Cercare il medicinale per il nome

Zovia 1/35 e Ipertensione

Risultato del controllo d'interazione tra il farmaco Zovia 1/35 e la malattia Ipertensione su sicurezza in caso d'uso simultaneo.

Risultato di controllo:

Zovia 1/35 <> Ipertensione

Rilevanza: 23.07.2019 Recensore: P.M. Shkutko, dott., in

Durante il controllo d'interazione, secondo le fonti autorevoli Drugs.com, Rxlist.com, Webmd.com, Medscape.com sono trovate le controindicazioni o gli effetti collaterali che possono danneggiare oppure intensificare l’effetto negativo in caso d'uso del farmaco in presenza di questa malattia concomitante.

Consumatore:

Il rischio di infarto del miocardio e ictus, compresi quelli connessi con l'uso di contraccettivi orali e alcuni l'uso di estrogeni, è aumentata nei pazienti con ipertensione. Inoltre, gli estrogeni (e progestinici) può elevare la pressione sanguigna e peggiorare l'ipertensione, così di aggravare il rischio. Clinicamente significativa della pressione arteriosa aumenti sono stati segnalati durante la terapia con estrogeni, in particolare in pazienti che ricevono dosi elevate o trattati con combinazioni di contraccettivi orali hanno un alta progestinici attività. Questi effetti anche aumentare con la durata della terapia e l'età del paziente. La terapia con estrogeni deve essere somministrato con cautela in pazienti con preesistente ipertensione. I pazienti devono essere monitorati per i cambiamenti in stato cardiovascolare, e la loro antipertensivi regime regolato o terapia con estrogeni ritirata come necessario. In pazienti che richiedono la contraccezione, i metodi alternativi dovrebbero essere considerati per coloro che sono ipertesi, di età superiore ai 35 anni e fumo.

Fonte

Crane MG, Harris JJ, Winsor W 3d "Hypertension, oral contraceptive agents, and conjugated estrogens." Ann Intern Med 74 (1971): 13-21
Levine AB, Teppa J, Mcgough B, Cowchock FS "Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives." Contraception 53 (1996): 255-7
"Product Information. Ogen (estropipate topical)" Pharmacia and Upjohn, Kalamazoo, MI.
"Product Information. Climara (estradiol)." Berlex, Richmond, CA.
Thorneycroft IH "Oral contraceptives and myocardial infarction." Am J Obstet Gynecol 163 (1990): 1393-7
Norris LA, Bonnar J "The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives." Br J Obstet Gynaecol 103 (1996): 261-7
"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho Pharmaceutical Corporation, Raritan, NJ.
Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989): 219-28
Martinelli I, Rosendaal FR, Vandenbroucke JP, Mannucci PM "Oral contraceptives are a risk factor for cerebral vein thrombosis." Thromb Haemost 76 (1996): 477-8
"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho Pharmaceutical Corporation, Raritan, NJ.
"Product Information. Ortho Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho Pharmaceutical Corporation, Raritan, NJ.
"Product Information. Estraderm (estradiol)." Ciba Pharmaceuticals, Summit, NJ.
"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Thorogood M, Mann J, Murphy M, Vessey M "Fatal stroke and use of oral contraceptives: findings from a case- control study." Am J Epidemiol 136 (1992): 35-45
Wren BG, Routledge DA "Blood pressure changes: oestrogens in climacteric women." Med J Aust 2 (1981): 528-31
"Product Information. Vivelle (estradiol)." Ciba Pharmaceuticals, Summit, NJ.
"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Lidegaard O "Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study." BMJ 306 (1993): 956-63
Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG "Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996): 505-10
Peterson HB, Lee NC "Long-term health risks and benefits of oral contraceptive use." Obstet Gynecol Clin North Am 17 (1990): 775-88
Stampfer MJ, Colditz GA, Willett WC, et al. "Postmenopausal estrogen and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study." N Engl J Med 325 (1991): 756-62
"Product Information. Ortho Dienestrol Cream (dienestrol topical)" Ortho McNeil Pharmaceutical, Raritan, NJ.
Williams RS "Benefits and risks of oral contraceptive use." Postgrad Med 92 (1992): 155-7
Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG, Debertribeiro M, Medina E, Artigas J, Shen H, Zhong YH, Zhang DW, "Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study." Lancet 348 (1996): 498-505
Piegsa K, Guillebaud J "Oral contraceptives and the risk of DVT." Practitioner 240 (1996): 544
"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical, Raritan, NJ.
"Product Information. Demulen (ethinyl estradiol-ethynodiol)." Searle, Skokie, IL.
The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA 273 (1995): 199-208
"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Schwartz J, Freeman R, Frishman W "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol 35 (1995): 1-16
Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989): 662-8
Leaf DA, Bland D, Schaad D, Neighbor WE, Scott CS "Oral contraceptive use and coronary risk factors in women." Am J Med Sci 301 (1991): 365-8
Crane MG, Harris JJ "Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system." Am J Med Sci 276 (1978): 33-55
Sidney S, Petitti DB, Quesenberry CP "Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women." Ann Intern Med 127 (1997): 501-8
Mishell DR "Contraception." N Engl J Med 320 (1989): 777-85
"Product Information. Estratab (esterified estrogens)" Solvay Pharmaceuticals Inc, Marietta, GA.
Barrett-Connor E, Bush TL "Estrogen and coronary heart disease in women." JAMA 265 (1991): 1861-7
"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories, Rockaway, NJ.
Jick H, Dinan B, Rothman KJ "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA 239 (1978): 1407-8
Rosenberg L, Palmer JR, Lesko SM, Shapiro S "Oral contraceptive use and the risk of myocardial infarction." Am J Epidemiol 131 (1990): 1009-16
Speroff L "Oral contraceptives and venous thromboembolism." Int J Gynaecol Obstet 54 (1996): 45-50
Farley TMM, Meirik O, Poulter NR, Chang CL, Marmot MG "Oral contraceptives and thrombotic diseases: impact of new epidemiological studies." Contraception 54 (1996): 193-5
Hannaford PC, Croft PR, Kay CR "Oral contraception and stroke. Evidence from the Royal College of General Practitioners' Oral Contraception Study." Stroke 25 (1994): 935-42
Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS "Noncontraceptive estrogens and myocardial infarction in young women." JAMA 244 (1980): 339-42
Thorogood M "Risk of stroke in users of oral contraceptives." JAMA 281 (1999): 1255-6
"Product Information. Ortho Novum 1/50 (mestranol-norethindrone)." Ortho Pharmaceutical Corporation, Raritan, NJ.
Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure." Am J Obstet Gynecol 114 (1972): 97-102
Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK "Stroke in users of low-dose oral contraceptives." N Engl J Med 335 (1996): 8-15
Derman RJ "Oral contraceptives and cardiovascular risk. Taking a safe course of action." Postgrad Med 88 (1990): 119-22
"Product Information. Estinyl Tablets (ethinyl estradiol)" Schering Corporation, Kenilworth, NJ.
Barrett-Connor E, Wingard DL, Criqui MH "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA 261 (1989): 1095-2100
Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994): 1062-71